$BDX (Becton, Dickinson and Company)

$BDX {{ '2017-04-24T14:58:54+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR$BCR common shareholders will be entitled to receive about $222.93 in cash and 0.5077 shares of $BDX stock per $BCR share, or a total of value of $317.00 per $BCR common share. This will be immediately accretive and is expected to generate high-single digit accretion to adjusted EPS in FY19.

$BDX {{ '2017-11-20T22:01:18+0000' | timeago}} • Announcement

$BDX has declared a quarterly dividend of $0.75 cents per common share, an increase of 2.7% from the previous quarter.  The dividend will be payable on Dec. 29, 2017 to holders of record on Dec. 8, 2017.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$BDX {{ '2017-11-02T13:12:06+0000' | timeago}} • Infographic

$BDX Becton, Dickinson and Company Earnings AlphaGraphic: Q4 2017 Highlights

$BDX {{ '2017-11-02T11:15:18+0000' | timeago}} • Announcement

On a stand-alone basis, $BDX expects FY18 revenues to increase 5-6% as reported, or 4-5% on a currency-neutral basis. Adjusted EPS is predicted to be between $10.55 and $10.65 on a stand-alone basis, which represents growth of about 12%.

$BDX {{ '2017-11-02T11:09:45+0000' | timeago}} • Announcement

$BDX reported quarterly revenues of $3.166Bil for 4Q17, down 2% YoY, primarily due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, revenues for the quarter grew 4.4%.

$BDX {{ '2017-11-02T11:04:23+0000' | timeago}} • Announcement

Medical technology company $BDX reported a jump in 4Q17 net income to $289MM, or $1.24 per share, compared to last year's $19MM, or $0.09 per share. This increase is primarily due to restructuring and other charges incurred in the prior-year due to the acquisition of CareFusion. On an adjusted basis, EPS grew 13.2% to $2.40.

$BDX {{ '2017-09-29T15:36:16+0000' | timeago}} • Announcement

Medical technology company $BDX has named Timothy M Ring and David F Melcher to its BoD, following completion the company’s acquisition of CR Bard Inc. Ring has been serving as Chairman and CEO of Bard since August 2003. Melcher, also a director of Bard, is President and CEO of the Aerospace Industries Association.

$BDX {{ '2017-08-15T12:16:07+0000' | timeago}} • Announcement

$BDX obtained 510(k) clearance from the U.S. FDA for the BD Bactec Standard Aerobic and Standard Anaerobic blood culture bottles in plastic. This marks further expansion of the blood culture bottles available in plastic across $BDX's industry-leading BD Bactec platform.

$BCR {{ '2017-08-09T13:54:30+0000' | timeago}} • Announcement

$BCR and $BDX have announced that they have received the approval of $BCR’s shareholders for the proposed acquisition of $BCR by $BDX in a stock and cash transaction. The proposed transaction remains subject to other conditions and approvals, and is presently expected to close in the fourth calendar quarter of 2017.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$BDX {{ '2017-05-02T10:50:46+0000' | timeago}} • Announcement

$BDX now expects FY17 EPS of $7.73-7.83, which represents growth of about 72-74%. On a currency-neutral basis, $BDX still sees adjusted EPS of $9.70-9.80, which includes an estimated 1.5 points of dilution related to the Respiratory Solutions divestiture. Including negative foreign current impact, $BDX still sees adjusted EPS of $9.35-9.45.

$BDX {{ '2017-05-02T10:47:45+0000' | timeago}} • Announcement

$BDX still expects FY17 revenue to decrease 3.5-4%, primarily due to the divestiture of the Respiratory Solutions business. The company continues to estimate that revenues for FY17 to increase 4.5-5.0% on a comparable, currency-neutral basis that excludes Respiratory Solutions and other divestitures that closed in FY16.

$BDX {{ '2017-05-02T10:46:32+0000' | timeago}} • Announcement

As a result of transformation in the U.S. dispensing business within Medication Management Solutions, $BDX's accounting for revenue recognition will change to reflect the new dispensing business model. $BDX sees an unfavorable impact to FY17 of about $50-60MM to revenues and about $0.20-0.25 to adjusted EPS.

$BDX {{ '2017-05-02T10:46:03+0000' | timeago}} • Announcement

$BDX reported a 1.6% rise in 2Q17 earnings driven by lower income tax provision. Net income rose to $344MM or $1.58 per share from $338MM or $1.56 per share last year. Revenue fell to $2.97Bil from $3.07Bil, due to the divestiture of the Respiratory Solutions business. Adjusted EPS increased to $2.30 from $2.18.

$BDX {{ '2017-04-24T15:32:49+0000' | timeago}} • Announcement

$BDX appointed Tom Polen as president of $BDX, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments, the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the $BCR businesses following the close of $BDX's acquisition of $BCR.

$BDX {{ '2017-04-24T15:02:53+0000' | timeago}} • Announcement

$BDX appointed Tom Polen as president of $BDX, effective immediately. In his new role, Polen will oversee $BDX's Medical and Life Sciences segments, as well as the new Interventional segment.

$BDX {{ '2017-04-24T15:00:46+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR. About $300MM of annual, pre-tax, run-rate cost synergies are expected by FY20. $BDX also expects to benefit from revenue synergies beginning in FY19. This is expected to improve $BDX's gross margins by about 300 basis points in FY18, increase $BDX's EPS growth trajectory to the mid-teens, and generate strong cash flow.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
SNE (Sony Corporation)
Tuesday, October 31 2017 - 7:30am
OMCL (Omnicell, Inc.)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm

AlphaGraphics you may like